News Of interest First CGM-enabled, waterproof insulin pump system now approved in Europe
If you are willing to test frequently and are motivated enough to use a pump we believe you should have one |
| First CGM-enabled, waterproof insulin pump system now approved in Europe |
 |
 |
 |
Animas® Vibe™, the First Integrated Offering from Animas Corporation and Dexcom, Inc., Receives European CE Mark Approval
As a CGM-enabled system, the Animas® Vibe™ insulin pump functions as a receiver for the Dexcom G4™ Sensor. The system delivers real-time glucose information, alerts for high and low readings, and glucose trend information, enabling patients to make more informed decisions to help control their disease.* Unlike currently available CGM-enabled pump systems, Animas® Vibe™ displays glucose trends in colour and is waterproof.**
Clinical studies have shown that adults aged 25 and older with type 1 diabetes who use CGM therapy to help manage their disease often experience significant improvements in glucose control.¹ Furthermore, patients who use insulin pump therapy in combination with CGM obtain lower HbA1c levels relative to baseline and relative to patients who use multiple daily injections and self-monitoring of blood glucose.² CGM-enabled systems, like Animas® Vibe™, provide patients with a more complete glucose picture (compared to fingersticks alone) – including customizable high and low alerts and rate-of-change alarms and trends. These features allow patients to make more informed decisions to help control their disease.* “Diabetes is a demanding disease. Companies like Dexcom and Animas work tirelessly to provide people living with diabetes relief in the day-to-day, hour-by-hour management that is required with this chronic condition,” said Dr. Anhalt. “By combining high-performance pumping with state-of-the-art CGM technology, we’re able to bring people with diabetes tools to better manage their disease.” Animas® Vibe™ marks the first integrated product offering from Animas Corporation, makers of high-performance insulin pump technology and Dexcom, Inc., the leader in continuous glucose sensing technologies. Now approved in Europe, the product will initially be available to people living with diabetes in the United Kingdom, Germany, France, Italy and Sweden. Animas® Vibe™ offers:
The International Diabetes Federation estimates that 285 million people around the world have diabetes. This accounts for approximately 2.8 million people in the U.K., 7.5 million in Germany, 3.9 million in Italy, 4.2 million in France, and 484,400 in Sweden respectively.³ References¹ New England Journal of Medicine. 2008; 359:1464-76. Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes. Tamborlane, W. Beck, R., Buckingham, B: Pgs. 1464- 1475 More Information
|
WEST CHESTER, PA, June 2, 2011 /PRNewswire/ — 
“The CE Mark approval for Animas® Vibe™ is a significant milestone for our R&D program and for people living with diabetes who are seeking better ways to manage their disease,” said Henry Anhalt, D.O., Chief Medical Officer, Animas Corporation. “Avoiding extreme highs and lows in glucose levels is crucial to controlling diabetes and reducing the risk of long-term diabetes complications. Animas® Vibe™ brings together leading pump and CGM technology to provide more freedom and flexibility to people living with diabetes.”